At present, a large number of pharmaceutical companies are actively responding to national policies, constantly adapting to the higher requirements brought by industrial changes, and continuing to steadily promote scientific and technological innovation
.
Affected by this, the research and development of drug clinical trials of pharmaceutical companies is also accelerating, and a pharmaceutical company recently announced on the same day that 3 drugs have obtained clinical trial approval notices and will carry out clinical trials
in the near future.
On November 16, Hengrui Pharmaceutical announced that Shandong Shengdi Pharmaceutical Co.
, Ltd.
, a subsidiary of the company, recently received the approval of the State Food and Drug Administration to issue the "Drug Clinical Trial Approval Notice" for HRS-1358 tablets and HRS-1780 tablets, and will carry out clinical trials
in the near future.
Among them, HRS-1358 tablets can inhibit the proliferation of tumor cells, overcome target protein mutation resistance and have higher selectivity
for target proteins than traditional small molecule drugs.
There are no similar drugs on the market at home and abroad, and there is no relevant sales data
.
Up to now, HRS-1358 related projects have invested a total of about 29.
73 million yuan
in R&D expenses.
HRS-1780 is an oral small molecule drug
clinically intended for the treatment of chronic kidney disease (CKD).
At present, the main drugs for the treatment of CKD include angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists
.
Up to now, HRS-1780 related projects have invested a total of about 14.
17 million yuan
in R&D expenses.
On the same day, the announcement showed that its subsidiary Shanghai Hengrui Pharmaceutical Co.
, Ltd.
also received approval from the National Medical Products Administration to issue the "Drug Clinical Trial Approval Notice" for SHR-7367 injection, and will carry out clinical trials
in the near future.
SHR-7367 injection is a humanized antibody independently developed by Hengrui Pharmaceutical, which is intended to be used for the treatment of advanced malignant tumors
.
SHR-7367 can exert anti-tumor effects
by specifically binding to tumor-associated antigens and activating immunoco-stimulating molecules, thereby activating multiple immune cells in the tumor microenvironment.
Industry analysts believe that the reason why many drugs have been approved for clinical trials one after another is mainly due to
the gradual harvest period of Hengrui Pharmaceutical's innovative drug pipeline.
It is understood that in recent years, Hengrui Pharmaceutical has been firmly increasing R&D investment, and in the first half of 2022, R&D investment increased by 12.
74% year-on-year to 2.
909 billion yuan, accounting for 28.
44% of sales revenue, of which 2.
184 billion yuan was spent in expensed R&D and 21.
36
% in R&D expense rate.
At present, Hengrui Pharmaceutical has 11 innovative drugs approved for marketing, and more than 60 innovative drugs are under clinical development
.
It is worth mentioning that Hengrui Pharmaceutical previously said on the investor interactive platform that the company will continue to vigorously promote the two development strategies of "scientific and technological innovation" and "internationalization", continue to increase investment in the research and development of innovative drugs, and steadily promote the internationalization
of research and development innovation and preparation products.
At the same time, it will also focus on the optimization and improvement of product structure, promote the sustainable development of the company through product innovation and upgrading and the expansion of diversified product pipelines, and promote the sustainable growth
of the company's performance.
In this regard, many institutions in the industry have expressed optimism
about the future development of Hengrui Pharmaceutical.
For example, Guojin Securities gave Hengrui Pharmaceutical a buy rating, and its analysis believes that Hengrui Pharmaceutical vigorously promotes scientific and technological innovation and internationalization strategy, and is expected to usher in a performance inflection point
in the second half of the year.
It is expected that Hengrui Pharmaceutical's net profit attributable to the parent in 2022-2024 will be 47/52/5.
9 billion yuan, corresponding to 48/44/38 times PE in 2022-2024, respectively, maintaining a "buy" rating
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
